5 Leading Radiopharmaceutical Manufacturers
Published:
Nuclear medicine is a specialized clinical field that utilizes radiopharmaceutical biologically active molecules chemically bound to a radioactive isotope to target specific cells, tissues, or organs in the human body. Over the last few years, these radioactive tracers have seen extensive adoption in clinical diagnostics and therapeutic treatments. This rapid growth is driven by their high affinity for target receptors, distinct biological specificity, and short radioactive half-lives.
Radiopharmaceuticals have overcome several clinical limitations, including poor target selectivity, systemic side effects, and the inability to monitor therapeutic impact in real time. These clinical advantages have generated significant traction from stakeholders in this domain and fueled a wave of biotech startups. It is important to highlight that the growth in this space is further fueled by advanced biological target identification, automated radiochemistry platforms and a strong surge in venture capital funding for next-generation treatments. Over recent years, several new manufacturers and CDMOs have entered the market, focusing on scaling specialized facilities to meet unmet needs in global isotope supply chains.
Roots Analysis has conducted an exhaustive study on Radiopharmaceutical Manufacturing Market featuring the current market landscape and future opportunities for companies engaged in healthcare, over a span of next 9 years.
Top Five Radiopharmaceutical Manufacturers
- BAMF Health
- Cardinal Health
- DUChembio
- Eckert & Ziegler
- PharmaLogic
The figure below highlights the top five radiopharmaceutical manufacturers:

Interested in exploring more than 120 industry players and close to 125 non-industry players manufacturing radiopharmaceuticals, along with their recent initiatives?
Discover Below the Details on Top 5 Radiopharmaceutical Manufacturers
Let us dive deep into the details of the top 5 radiopharmaceutical manufacturers. It is essential to note that the selection of top players can differ substantially according to the defined criteria.
1. BAMF Health
Company Overview
BAMF Health is a pioneering company in the radiopharmaceutical and theragnostic domain. It operates one of the world’s most advanced, vertically integrated platforms for precision medicine, to make molecular imaging and therapy accessible and affordable for patients with cancer. They partner with pharma companies for preclinical-to-commercial production of tracers, supporting high-volume, flexible manufacturing to accelerate FDA approvals and market adoption.
BAMF Health: Company Overview
![]() |
Company Name | Year of Establishment | Headquarters | Number of Employees |
| BAMF Health | 2018 | US | 51-200 |
Recent Developments
In May 2026, Sentara Health and BAMF Health launched a joint venture, highlighting plans to establish Virginia's first comprehensive, vertically integrated theragnostic program, which combines advanced radiopharmaceutical production, molecular imaging, molecular therapy, and clinical trials.
To know more about the recent initiatives of BAMF Health and other companies manufacturing radiopharmaceuticals access full report.
2. Cardinal Health
Company Overview
Cardinal Health is a global healthcare company that operates through two business segments, namely, pharmaceutical, and medical segment. Within the pharmaceutical segment, the company offers generic and branded pharmaceuticals, over-the-counter healthcare products, and radiopharmaceutical to its customers. It is worth highlighting that the company delivers more than 12 million radiopharmaceutical doses annually through 130+ nuclear pharmacies located across the globe. In addition, the company claims to have the end-to-end capabilities to offer contract services for the development and manufacturing of a wide range of radiopharmaceutical (including diagnostic, therapeutic and theranostic radiopharmaceutical).
Cardinal Health: Company Overview
![]() |
Company Name | Year of Establishment | Headquarters | Number of Employees |
| Cardinal Health | 1971 | US | 10,001+ |
Recent Developments
In April 2026, Cardinal Health announced expansion of its Actinium-225 (Ac-225) production capabilities at its Center for Theranostics Advancement. This expansion aims to support the company’s strategy to advance cGMP-compliant Ac-225 supply for investigational therapeutic drug products, potentially accelerating its path toward robust commercial-scale manufacturing and broader clinical use for novel targeted alpha cancer therapies.
To know more about Cardinal Health and other companies manufacturing radiopharmaceuticals, access full report.
3. DUChemBio
Company Overview
DuChemBio is a technology-driven contract development and manufacturing organization that possess the required capabilities for the development and manufacturing of diagnostic, therapeutic and theranostic radiopharmaceutical. The company’s service portfolio includes services related to manufacturing, technology transfer, packaging, purification and supply of radiopharmaceutical at preclinical, clinical and commercial scale. Further, the company claims to have the largest radiopharmaceutical manufacturing network in South Korea.
DUChembio: Company Overview
![]() |
Company Name | Year of Establishment | Headquarters | Number of Employees |
| DuChemBio | 2002 | South Korea | 51-200 |
Recent Developments
In July 2026, DuChemBio announced a merger with its subsidiary, Radio D&S Labs with the aim to internalize research and development capabilities. This also supports the company's strategy to strengthen its contract manufacturing business, potentially accelerating the creation of new radiopharmaceutical to meet growing demand for advanced cancer therapeutics.
To know more about DuChemBio and other companies manufacturing radiopharmaceuticals, access full report.
4. Eckert & Ziegler
Company Overview
Eckert & Ziegler is a technology-driven company that operates through two business segments, namely, medical, and radioisotope. Within the medical segment, the company offers radiopharmaceutical, radio chemicals and medical devices for the diagnosis and treatment of oncological and neurological disorders. In addition, the company claims to have end-to-end capabilities to offer contract services for the development and manufacturing of a wide range of radiopharmaceutical (including diagnostic, therapeutic and theranostic radiopharmaceutical). As per the company’s website it also conducts customized studies on radiopharmaceutical for clinical trials.
Eckert & Ziegler: Company Overview
![]() |
Company Name | Year of Establishment | Headquarters | Number of Employees |
| Eckert & Ziegler | 1997 | Germany | 51-200 |
Recent Developments
In February 2026, Eckert & Ziegler entered into agreement with Molecular Partners to advance Radio-DARPin therapeutics, utilizing a proprietary platform to deliver Actinium-225 and Lutetium-177 payloads. The collaboration focuses on accelerating the technical development, candidate selection, and manufacturing of these targeted therapies, aiming to expand treatment options for various cancers.
To know more about the recent initiatives of Eckert & Ziegler and other companies manufacturing radiopharmaceuticals, access full report.
5. PharmaLogic
Company Overview
PharmaLogic is a US-based contract development and manufacturing organization that is engaged in the development and production of a wide range of radiopharmaceutical. Leveraging its elaborate service portfolio, the company claims to offer end-to-end product development services, ranging for preclinical development to commercialization of diagnostic, therapeutic and theranostic radiopharmaceutical. It is worth highlighting that the company uses its own distribution network to deliver its radiopharmaceutical doses across North America.
PharmaLogic: Company Overview
![]() |
Company Name | Year of Establishment | Headquarters | Number of Employees |
| PharmaLogic | 1993 | US | 501-1000 |
Recent Developments
In May 2026, PharmaLogic and Ratio Therapeutics expanded their manufacturing agreement, showcasing a plan to boost the production of the cancer therapy candidate [Ac-225] RTX-2358 at its Idaho Falls facility.
To know more about PharmaLogic and other companies manufacturing radiopharmaceuticals, access full report.
What About Other Companies Manufacturing Radiopharmaceutical Around the World?
The above article features the top five radiopharmaceutical manufacturers selected from a pool of around 245 industry and non-industry players that we have compiled. If you're interested, you can download the Sample Report on this topic by Roots Analysis. For personalized assistance in identifying the most relevant solutions based on your specific criteria, please don't hesitate to reach out to us at sales@rootsanalysis.com.
Sources:
- https://www.auntminnie.com/clinical-news/molecular-imaging/news/15826313/sentara-health-bamf-health-launch-theranostics-joint-venture
- https://newsroom.cardinalhealth.com/2026-04-01-Cardinal-Health-expands-Actinium-225-production-capacity-to-support-growing-demand-for-novel-cancer-therapies
- https://en.fnnews.com/news/202607230856316266
- https://investors.molecularpartners.com/news-releases/news-release-details/molecular-partners-signs-development-agreement-eckert-ziegler/
- https://www.biospace.com/press-releases/pharmalogic-and-ratio-therapeutics-expand-manufacturing-collaboration-to-support-clinical-development-of-ac-225rtx-2358




